Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 326 (Rixubis) in Pediatric Hemophilia B
NCT01488994Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2011
- Primary completion
- May 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of trenonacog alfa in hemophilia B (HB), sponsored by Takeda. Started Dec 2011; status: completed.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01488994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488994.